GAIN THERAPEUTICS INC (GANX) Stock Price, Quote, News and Overview
NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD
GANX Quote, Performance and Key Statistics
GAIN THERAPEUTICS INC
NASDAQ:GANX (2/4/2025, 4:11:17 PM)
After market: 2.22 +0.01 (+0.45%)2.21
+0.05 (+2.31%)
The current stock price of GANX is 2.21 USD. In the past month the price decreased by -9.05%. In the past year, price decreased by -56.15%.
GANX Latest News, Press Releases and Analysis
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and...
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform...
GANX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About GANX
Company Profile
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Company Info
GAIN THERAPEUTICS INC
4800 Hampden Lane, Suite 200
Bethesda MARYLAND 20814 US
CEO: Eric Richman
Employees: 31
Company Website: https://www.gaintherapeutics.com/
Investor Relations: http://gaintherapeutics.com/investors-media/overview.html
Phone: 13015001556
GANX FAQ
What is the stock price of GANX?
The current stock price of GANX is 2.21 USD.
What is the symbol for GAIN THERAPEUTICS INC stock?
The exchange symbol of GAIN THERAPEUTICS INC is GANX and it is listed on the Nasdaq exchange.
On which exchange is GANX stock listed?
GANX stock is listed on the Nasdaq exchange.
Is GANX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GANX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GANX.
Does GANX stock pay dividends?
GANX does not pay a dividend.
What is the Price/Earnings (PE) ratio of GANX?
GANX does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of GANX stock?
The outstanding short interest for GANX is 1.52% of its float.
GANX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GANX. When comparing the yearly performance of all stocks, GANX is a bad performer in the overall market: 89.83% of all stocks are doing better.
GANX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GANX. GANX may be in some trouble as it scores bad on both profitability and health.
GANX Financial Highlights
Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS decreased by 35.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -148.74% | ||
| ROE | -239.83% | ||
| Debt/Equity | 0.04 |
GANX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to GANX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 43.65% and a revenue growth -100% for GANX